GSK
GSK
729 hedge funds and large institutions have $10.9B invested in GSK in 2014 Q4 according to their latest regulatory filings, with 106 funds opening new positions, 282 increasing their positions, 242 reducing their positions, and 70 closing their positions.
62% more call options, than puts
Call options by funds: $202M | Put options by funds: $124M
51% more first-time investments, than exits
New positions opened: 106 | Existing positions closed: 70
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
17% more repeat investments, than reductions
Existing positions increased: 282 | Existing positions reduced: 242
4% more funds holding
Funds holding: 702 → 729 (+27)
0.24% less ownership
Funds ownership: 4.41% → 4.18% (-0.24%)
12% less capital invested
Capital invested by funds: $12.3B → $10.9B (-$1.43B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$238M |
| 2 |
SOMRS
State of Michigan Retirement System
Lansing,
Michigan
|
+$119M |
| 3 |
Jane Street
New York
|
+$81.5M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$74.5M |
| 5 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
+$63.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
-$655M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$302M |
| 3 |
State Farm Mutual Automobile Insurance
Bloomington,
Illinois
|
-$105M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$97.9M |
| 5 |
MAA
Managed Account Advisors
Jersey City,
New Jersey
|
-$81.3M |
GSK Hedge Fund Activity: Q4 2014 in Review
729 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q4 2014, worth a combined $10.9B — down 12% from $12.3B a quarter earlier.
Buyers outnumbered sellers: 106 funds opened new GSK positions and 70 closed out — a net gain of 36 holders — while 282 added to existing stakes and 242 trimmed.
The largest buyer was Waddell & Reed Financial, adding an estimated $238M. The largest seller was Dodge & Cox, cutting an estimated $655M.
- 729 institutional investors held GSK (GSK) as of Q4 2014, up from 702 in Q3 2014.
- Funds reported $10.9B of GSK stock for Q4 2014, down 12% quarter-over-quarter.
- 106 funds opened new GSK positions in Q4 2014 and 70 closed out, a net change of +36 holders.
- The largest GSK buyer in Q4 2014 was Waddell & Reed Financial, an estimated $238M added.
- The largest GSK seller in Q4 2014 was Dodge & Cox, an estimated $655M sold.
Based on aggregated 13F filings for Q4 2014.